Crystal and Lilly reach a $345 million AI large molecule research and development cooperation in the dual antibody field.

On November 5th, Jingtai Technology announced that its wholly-owned subsidiary Ailux has entered into a strategic partnership and platform authorization agreement with Lilly, with a total agreement value of up to $345 million, including tens of millions of dollars in upfront payments and near-term milestone payments. Under the agreement, Lilly may nominate multiple target groups, and Ailux is responsible for designing and optimizing dual-antibody candidate drugs. Ailux is eligible to receive tens of millions of dollars in upfront payments and near-term milestone payments, as well as subsequent research and development, registration, and commercial milestone payments. In addition, Lilly also has the right to use Ailux's artificial intelligence dual-antibody design platform.